QualityStocksNewsBreaks – BiondVax Pharmaceuticals Ltd. (NASDAQ: BVXV) Enters Development, Commercialization Agreement for Novel Anti-IL-17 Antibody
BiondVax Pharmaceuticals (NASDAQ: BVXV), a biotechnology company focused on developing, manufacturing and commercializing innovative immunotherapeutic products primarily for the treatment of infectious and autoimmune diseases, has signed an exclusive worldwide license agreement. The agreement, which is part of its ongoing collaboration with the Max Planck Society and the University Medical Center Gottingen (“UMG”), outlines the development and commercialization of VHH antibodies (NanoAbs) targeting Interleukin-17 (“IL-17”) as treatments for all potential indications; the agreement notes that development will start with a focus on psoriasis and psoriatic arthritis. According to the announcement, BiondVax will lead out on the development and commercialization of…